Literature DB >> 20576214

Interactions between rheumatologists and cardio-/pulmonologists in the assessment and use of outcome measures in pulmonary arterial hypertension related to systemic sclerosis.

Doerte Huscher1, David Pittrow, Oliver Distler, Christopher P Denton, Ivan Foeldvari, Marc Humbert, Marco Matucci-Cerinic, Otylia Kowal-Bielecka, Jerome Avouac, Frank Behrens, Peter Nash, Christian F Opitz, Lewis J Rubin, James R Seibold, Vibeke Strand, Daniel E Furst.   

Abstract

OBJECTIVES: Pulmonary arterial hypertension in patients with systemic sclerosis is a disease involving multiple organ systems. We investigated the differences in perceptions of how to measure PAH-SSc among cardiologists, pulmonologists and rheumatologists. We also examined how a Delphi exercise can improve agreement among these subspecialties.
METHODS: The outcome measures derived from the recent Delphi survey were used for a detailed analysis of the contribution of the various specialties contributing to it. We compared rheumatologists and cardiologist/pulmonologists with regards to preferences and ratings of various endpoints and the actual use of tools to measure these outcomes. We also examined the effects of the Delphi process among these groups.
RESULTS: We could show that the different expert groups each tended to contribute differently to the development of the core set of measures and that interactions in the Delphi process resulted in convergence of rankings. Despite agreement on the high importance of the domains in the Delphi, the use of tools within those domains was sometimes divergent and dependent on specialty.
CONCLUSIONS: Based on these results, use of differing tools in the diagnosis and treatment of PAH-SSc can be anticipated. Further, the convergence of results provides evidence, for the first time, for the ability of various approaches in these disciplines to reach harmonious endpoints of care for PAHSSc patients. A collaborative, interdisciplinary approach is advantageous for PAH-SSc patients.

Entities:  

Mesh:

Year:  2010        PMID: 20576214

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  4 in total

Review 1.  Pulmonary arterial hypertension associated with systemic sclerosis.

Authors:  Stephen C Mathai; Paul M Hassoun
Journal:  Expert Rev Respir Med       Date:  2011-04       Impact factor: 3.772

Review 2.  Treatment of pulmonary arterial hypertension in connective tissue disease.

Authors:  Ekkehard Grünig
Journal:  Drugs       Date:  2012-05-28       Impact factor: 11.431

3.  Systemic sclerosis-associated pulmonary hypertension: why disease-specific composite endpoints are needed.

Authors:  Christopher P Denton; Jerome Avouac; Frank Behrens; Daniel E Furst; Ivan Foeldvari; Marc Humbert; Doerte Huscher; Otylia Kowal-Bielecka; Marco Matucci-Cerinic; Peter Nash; Christian F Opitz; David Pittrow; Lewis J Rubin; James R Seibold; Oliver Distler
Journal:  Arthritis Res Ther       Date:  2011-06-20       Impact factor: 5.156

4.  Delphi consensus recommendation for optimization of pulmonary hypertension therapy focusing on switching from a phosphodiesterase 5 inhibitor to riociguat.

Authors:  Franck F Rahaghi; Vijay P Balasubramanian; Robert C Bourge; Charles D Burger; Murali M Chakinala; Michael S Eggert; Jean M Elwing; Jeremy Feldman; Christopher King; James R Klinger; Stephen C Mathai; John Wesley McConnell; Harold I Palevsky; Ricardo Restrepo-Jaramillo; Zeenat Safdar; Jeffrey S Sager; Namita Sood; Roxana Sulica; R James White; Nicholas S Hill
Journal:  Pulm Circ       Date:  2022-04-07       Impact factor: 2.886

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.